3 Stocks Improving Performance Of The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 59 points (0.3%) at 18,083 as of Monday, May 4, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,918 issues advancing vs. 1,077 declining with 158 unchanged.

The Health Care sector currently sits up 1.2% versus the S&P 500, which is up 0.4%. Top gainers within the sector include Intercept Pharmaceuticals ( ICPT), up 5.3%, ISIS Pharmaceuticals ( ISIS), up 4.1%, Incyte ( INCY), up 3.6%, St Jude Medical ( STJ), up 2.1% and Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.1%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Biogen ( BIIB) is one of the companies pushing the Health Care sector higher today. As of noon trading, Biogen is up $2.13 (0.6%) to $388.35 on average volume. Thus far, 785,170 shares of Biogen exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $387.01-$393.89 after having opened the day at $389.45 as compared to the previous trading day's close of $386.22.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $88.0 billion and is part of the drugs industry. Shares are up 13.8% year-to-date as of the close of trading on Friday. Currently there are 12 analysts who rate Biogen a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Pfizer ( PFE) is up $0.24 (0.7%) to $34.32 on light volume. Thus far, 7.5 million shares of Pfizer exchanged hands as compared to its average daily volume of 29.3 million shares. The stock has ranged in price between $34.05-$34.36 after having opened the day at $34.11 as compared to the previous trading day's close of $34.08.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $208.3 billion and is part of the drugs industry. Shares are up 9.4% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, expanding profit margins and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Pfizer Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Gilead ( GILD) is up $1.90 (1.8%) to $106.91 on average volume. Thus far, 8.6 million shares of Gilead exchanged hands as compared to its average daily volume of 11.7 million shares. The stock has ranged in price between $105.22-$107.50 after having opened the day at $105.65 as compared to the previous trading day's close of $105.01.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $149.1 billion and is part of the drugs industry. Shares are up 11.4% year-to-date as of the close of trading on Friday. Currently there are 14 analysts who rate Gilead a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists